Trademark Overview
On Wednesday, July 3, 2024, a trademark application was filed for ALCHEMAB with the United States Patent and Trademark Office. The USPTO has given the ALCHEMAB trademark a serial number of 79403954. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, September 5, 2024. This trademark is owned by Alchemab Therapeutics Ltd. The ALCHEMAB trademark is filed in the Pharmaceutical Products, Computer & Software Products & Electrical & Scientific Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Software for the testing and/or identification of antibodies; software in the field of antibody technology; software for use in or relating to the development of pharmaceutical preparations incorporating antibodies and/or antibody technology.
Pharmaceutical preparations incorporating antibodies and/or antibody technology; chemical preparations for medical and pharmaceutical purposes incorporating antibodies and/or antibody technology; antibodies; diagnostic preparations involving the testing and/or identification of antibodies for medical purposes.
Medical diagnostic services involving the testing and/or identification of antibodies; medical testing, analysis and diagnostic services in the field of antibodies; information, advisory and consultancy services in relation to all of the aforesaid.
Research and development services in the field of antibodies and/or antibody technology; drug development and discovery services in relation to pharmaceutical preparations incorporating antibodies and/or antibody technology; antibody discovery services; development and testing of computing methods, algorithms and software for the testing and/or identification of antibodies; development and testing of computing methods, algorithms and software in the field of antibody technology; development and testing of computing methods, algorithms and software for use in or relating to the development of pharmaceutical preparations incorporating antibodies and/or antibody technology; information, advisory and consultancy services in relation to all of the aforesaid.